The Impact of Hypothermia on the Pharmacokinetics of Drugs Used in Neonates and Young Infants

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10313590" target="_blank" >RIV/00216208:11110/15:10313590 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10313590

Výsledek na webu

<a href="http://dx.doi.org/10.2174/1381612821666150901110929" target="_blank" >http://dx.doi.org/10.2174/1381612821666150901110929</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1381612821666150901110929" target="_blank" >10.2174/1381612821666150901110929</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Impact of Hypothermia on the Pharmacokinetics of Drugs Used in Neonates and Young Infants

Popis výsledku v původním jazyce

Therapeutic hypothermia (HT) is frequently used in neonates with hypoxic-ischemic encephalopathy and young infants during cardiopulmonary bypass (CPB). Hypothermia and CPB result in physiological changes contributing to pharmacokinetic (PK) and pharmacodynamic (PD) changes. Changes in the absorption, the volume of distribution (Vd) and the total body clearance (CL) of drugs used during hypothermia and CPB might lead to the interindividual PK variability resulting in either insufficient or toxic plasma concentrations and have an impact on the biodisposition and action of drugs. Both under-or overdosing of medicines in these critically ill patients may contribute to a worse overall outcome. Overall, hypothermia decreases CL but may decrease or increase Vd by changing intravascular blood volume, organ perfusion and enzymatic metabolic processes. In addition, maturational as well as organ specific changes may occur during hypothermia superimposed on the underlying disease and/or procedures

Název v anglickém jazyce

The Impact of Hypothermia on the Pharmacokinetics of Drugs Used in Neonates and Young Infants

Popis výsledku anglicky

Therapeutic hypothermia (HT) is frequently used in neonates with hypoxic-ischemic encephalopathy and young infants during cardiopulmonary bypass (CPB). Hypothermia and CPB result in physiological changes contributing to pharmacokinetic (PK) and pharmacodynamic (PD) changes. Changes in the absorption, the volume of distribution (Vd) and the total body clearance (CL) of drugs used during hypothermia and CPB might lead to the interindividual PK variability resulting in either insufficient or toxic plasma concentrations and have an impact on the biodisposition and action of drugs. Both under-or overdosing of medicines in these critically ill patients may contribute to a worse overall outcome. Overall, hypothermia decreases CL but may decrease or increase Vd by changing intravascular blood volume, organ perfusion and enzymatic metabolic processes. In addition, maturational as well as organ specific changes may occur during hypothermia superimposed on the underlying disease and/or procedures

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Pharmaceutical Design

ISSN

1381-6128

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

39

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

20

Strana od-do

5705-5724

Kód UT WoS článku

000365044900012

EID výsledku v databázi Scopus

2-s2.0-84957704892